The question of CBD vs THC for pain is one that millions of people are trying to answer for themselves, often with limited guidance. Online forums are full of personal anecdotes. Product labels make sweeping claims. Dispensary staff offer recommendations based on customer feedback rather than controlled data. And physicians — even those sympathetic to cannabis medicine — frequently admit they lack the training to provide evidence-based cannabinoid recommendations for pain.

This article cuts through the noise. We reviewed published clinical trials, systematic reviews, and meta-analyses to lay out what the evidence actually shows about CBD and THC for different types of pain. Where the data is strong, we will say so. Where it is weak or contradictory, we will say that too.

How CBD and THC Work on Pain: Different Mechanisms, Different Effects

CBD and THC are both cannabinoids derived from the cannabis plant, but they interact with the body’s endocannabinoid system in fundamentally different ways. Understanding these mechanisms is essential to understanding why one might work better than the other for a given type of pain.

THC’s Pain Pathway

THC (delta-9-tetrahydrocannabinol) binds directly to CB1 receptors in the brain and central nervous system. This binding produces several effects relevant to pain:

  • Central analgesic effect: THC reduces the brain’s processing of pain signals, not by blocking the signal at its source but by altering how the brain interprets it. Patients often report that the pain is still present but less bothersome — a phenomenon known as altered pain affect.
  • Descending inhibition: THC activates descending pain-inhibition pathways from the brainstem, which can suppress pain signal transmission in the spinal cord.
  • Anti-inflammatory action: THC has moderate anti-inflammatory properties through both CB1 and CB2 receptor activation, though this is secondary to its central effects.
  • Muscle relaxation: THC reduces muscle spasticity, which is relevant for musculoskeletal pain conditions.

The trade-off is psychoactivity. The same CB1 receptor binding that produces analgesia also produces the “high” — euphoria, altered perception, impaired short-term memory, and potential anxiety at higher doses.

CBD’s Pain Pathway

CBD (cannabidiol) does not bind directly to CB1 or CB2 receptors with significant affinity. Instead, it influences pain through several indirect mechanisms:

  • TRPV1 receptor activation: CBD activates vanilloid receptors involved in pain perception and inflammation, producing a desensitizing effect over time.
  • Adenosine reuptake inhibition: CBD increases adenosine signaling, which has anti-inflammatory and immunomodulatory effects.
  • 5-HT1A receptor agonism: CBD activates serotonin receptors involved in pain modulation and mood regulation.
  • PPARγ activation: CBD activates peroxisome proliferator-activated receptors, which regulate genes involved in inflammation.
  • Endocannabinoid enhancement: CBD inhibits the enzyme FAAH, which breaks down anandamide (the body’s endogenous cannabinoid). Higher anandamide levels may contribute to pain relief through indirect CB1 activation.

CBD does not produce psychoactive effects, which makes it accessible to people who cannot or do not want to experience intoxication.

For a deeper dive into the molecular differences between these compounds, see our THC vs. CBD comparison guide.

What the Clinical Trial Evidence Shows by Pain Type

The quality and quantity of clinical evidence varies significantly by pain type. Here is what controlled studies have found.

Neuropathic Pain

Neuropathic pain — caused by nerve damage from conditions like diabetes, chemotherapy, HIV, multiple sclerosis, or spinal cord injury — has the strongest evidence base for cannabinoid treatment.

THC: Multiple randomized controlled trials (RCTs) have demonstrated that inhaled and oral THC reduces neuropathic pain scores by 30% or more compared to placebo. A landmark 2015 systematic review in the Journal of the American Medical Association found moderate-quality evidence supporting cannabinoids (primarily THC-containing preparations) for chronic neuropathic pain. The effect size is comparable to other second-line neuropathic pain treatments like gabapentin and duloxetine.

CBD: Evidence for CBD alone in neuropathic pain is limited. A small number of preclinical studies and case series suggest benefit, but no large RCTs have evaluated CBD monotherapy for neuropathic pain. The clinical data that does exist largely comes from combination THC:CBD products (like nabiximols/Sativex), making it difficult to isolate CBD’s contribution.

Verdict: For neuropathic pain, THC has meaningfully stronger clinical evidence. CBD may contribute in combination formulations, but as a standalone treatment, the evidence is insufficient to draw conclusions.

Our cannabis and chronic pain research overview covers the broader evidence base in greater detail.

Inflammatory Pain

Inflammatory pain — from conditions like rheumatoid arthritis, inflammatory bowel disease, and acute injuries — involves a different set of mechanisms than neuropathic pain.

THC: Animal studies consistently show anti-inflammatory effects, but human clinical trials specifically targeting inflammatory pain with THC are sparse. Most of the human data comes from studies on conditions where inflammation is one component (like MS-related pain), making it difficult to isolate the anti-inflammatory contribution.

CBD: This is where CBD’s evidence is more promising. Several preclinical studies demonstrate robust anti-inflammatory effects through multiple pathways. Human data is growing:

  • A 2022 randomized trial found that topical CBD gel reduced knee pain in osteoarthritis patients compared to placebo
  • An open-label study of CBD in inflammatory bowel disease showed reduced inflammatory markers in a subset of patients
  • Multiple small trials in rheumatoid arthritis have shown symptom improvement with CBD-rich cannabis preparations

However, the human trial data remains limited by small sample sizes, inconsistent dosing, and variable product quality.

Verdict: CBD has a stronger theoretical basis for inflammatory pain and emerging clinical support. THC has anti-inflammatory properties but is less studied specifically for this pain type. Combination approaches may be most effective.

For comprehensive CBD pain evidence, see our CBD for pain clinical evidence review.

Musculoskeletal Pain

Musculoskeletal pain — back pain, muscle strains, joint pain from overuse — is the most common pain type and one of the most common reasons people report using cannabis.

THC: THC’s muscle relaxant properties are well-established. Nabiximols (a 1:1 THC:CBD spray) is approved in multiple countries for MS-related spasticity. For general musculoskeletal pain, however, controlled trial data is thin. Most evidence comes from observational studies and patient surveys, which consistently report benefit but are subject to significant bias.

CBD: Topical CBD products are enormously popular for musculoskeletal pain, and there is a growing body of evidence supporting their use. CBD’s anti-inflammatory properties, combined with the activation of peripheral TRPV1 receptors when applied topically, provide a plausible mechanism. Clinical evidence is emerging but still early-stage.

Verdict: Neither CBD nor THC has strong RCT evidence for general musculoskeletal pain as a standalone treatment. Patient-reported outcomes are consistently positive for both, but controlled data is needed.

Topical vs. Oral: Route of Administration Matters

How you take a cannabinoid matters as much as which one you choose. The route of administration affects bioavailability, onset, duration, and the types of pain it can address.

Oral CBD

  • Bioavailability: 6% to 19% (highly variable depending on formulation and whether taken with fat)
  • Onset: 30 minutes to 2 hours
  • Duration: 4 to 8 hours
  • Best for: Systemic inflammation, widespread pain, conditions requiring sustained blood levels
  • Limitations: High first-pass metabolism in the liver means most of the dose is broken down before reaching circulation. Doses need to be substantially higher than what many commercial products contain.

Inhaled THC

  • Bioavailability: 10% to 35%
  • Onset: Minutes
  • Duration: 1 to 4 hours
  • Best for: Acute pain episodes, breakthrough pain, conditions where rapid relief is needed
  • Limitations: Respiratory concerns with smoked cannabis; vaporization mitigates but does not eliminate these risks. Short duration means frequent re-dosing for chronic conditions.

Topical Application

  • Bioavailability: Low systemic absorption (which is the point — keeps effects local)
  • Onset: 15 to 45 minutes
  • Duration: 2 to 6 hours depending on formulation
  • Best for: Localized pain, joint pain, muscle soreness, inflammation at a specific site
  • Limitations: Does not penetrate deeply enough for some conditions. Quality and concentration vary enormously between products.

Our guide to cannabis topicals and creams covers product selection, concentration guidelines, and what to look for on labels.

Dosing Protocols: What the Research Uses

One of the biggest problems in consumer cannabis use for pain is dosing. Most people either underdose (and conclude cannabis does not work for them) or overdose THC (and experience unpleasant side effects that discourage continued use).

Clinical trials provide useful dosing frameworks:

THC Dosing for Pain

  • Starting dose: 2.5 mg oral or one small inhalation
  • Titration: Increase by 2.5 mg every 2 to 3 days until adequate relief or side effects emerge
  • Typical effective range: 5 to 20 mg daily for chronic pain
  • Upper range in studies: 30 to 40 mg daily (associated with more side effects and diminishing marginal returns)

CBD Dosing for Pain

  • Starting dose: 25 mg oral twice daily
  • Titration: Increase by 25 mg every week
  • Typical effective range in studies: 50 to 150 mg daily for pain conditions
  • Higher doses used in research: 300 to 600 mg daily for anxiety and seizure disorders (though most pain studies use lower amounts)
  • Topical: Products should contain at least 8 mg/mL CBD to have a reasonable chance of efficacy based on available data

Combination THC:CBD

Several studies suggest that combining THC and CBD produces better pain relief than either alone, at lower doses of each. CBD may modulate THC’s psychoactive effects, allowing patients to tolerate higher analgesic doses without excessive intoxication.

  • Common research ratio: 1:1 THC to CBD
  • Starting combination dose: 2.5 mg THC + 2.5 mg CBD
  • Typical effective range: 5 to 15 mg each daily

Use our pain relief method comparison tool to input your pain type, severity, and preferences — including whether you want to avoid psychoactive effects — and get evidence-based cannabinoid recommendations tailored to your situation.

What Doctors Actually Recommend

Physicians who specialize in cannabinoid medicine have developed practical approaches that balance the evidence base with clinical experience. The general consensus among these practitioners:

  1. Start with CBD for inflammatory conditions and mild to moderate pain — Lower risk profile, no psychoactivity, and reasonable evidence for anti-inflammatory effects
  2. Add THC for neuropathic pain or when CBD alone is insufficient — Stronger evidence base for nerve-related pain, but requires careful titration
  3. Use combinations for complex or severe pain — The entourage effect (whether fully validated or not) is consistently reported by patients, and the 1:1 ratio has the most clinical support
  4. Match the route to the pain — Topical for localized issues, oral for systemic conditions, inhaled for breakthrough episodes
  5. Document and adjust — Keep a pain diary tracking dose, timing, product, and pain levels. Cannabinoid therapy requires more patient engagement than taking a standard pharmaceutical.

It is critical to discuss cannabinoid use with your healthcare provider, especially if you take other medications. Our guide to cannabis and drug interactions covers known interactions with common prescription drugs.

Limitations of the Current Research

Intellectual honesty requires acknowledging where the evidence falls short:

  • Most RCTs are small. Sample sizes of 30 to 100 participants are common. Large Phase III trials with thousands of subjects — the standard for pharmaceutical approval — are rare in cannabinoid pain research.
  • Product inconsistency. Studies use different cannabis products, formulations, and delivery methods, making direct comparison difficult.
  • Blinding challenges. THC’s psychoactive effects make true blinding nearly impossible. Participants often know whether they received the active treatment, which can inflate reported benefits.
  • Short duration. Most pain studies last 2 to 12 weeks. Chronic pain is a long-term condition, and the long-term efficacy and safety of cannabinoids for pain remain understudied.
  • Publication bias. Positive results are more likely to be published than null results, potentially overstating the evidence base.
  • CBD market quality. Many commercially available CBD products contain less CBD than labeled, contain undisclosed THC, or include contaminants. Study results using pharmaceutical-grade CBD may not translate to consumer products.

For a comprehensive introduction to CBD including quality considerations, see our complete guide to CBD.

Practical Recommendations

Based on the totality of the available evidence:

If your primary concern is neuropathic pain: THC or a THC:CBD combination has the strongest evidence. Start low, titrate slowly, and use the minimum effective dose.

If your primary concern is inflammatory pain: Start with oral CBD at adequate doses (50+ mg daily). If insufficient, consider adding a low dose of THC or using a combination product.

If your primary concern is localized musculoskeletal pain: Try a high-concentration topical CBD product first. If inadequate, consider topical THC:CBD combinations or add oral supplementation.

If you cannot use THC (drug testing, psychoactive sensitivity, personal preference): CBD alone is a reasonable option, but set realistic expectations. The evidence is weaker for CBD monotherapy than for THC or combination approaches in most pain types.

If you are taking other medications: Consult with a healthcare provider. Both CBD and THC interact with cytochrome P450 enzymes involved in drug metabolism, potentially affecting levels of other medications you take.

Frequently Asked Questions

Is CBD or THC better for chronic pain?

It depends on the type of chronic pain. For neuropathic pain (nerve-related), THC has stronger clinical evidence. For inflammatory pain (arthritis, autoimmune conditions), CBD shows more promise. For many chronic pain patients, a combination of both cannabinoids at a 1:1 ratio may provide the best relief with manageable side effects.

How much CBD should I take for pain?

Clinical studies typically use 50 to 150 mg of CBD daily for pain conditions, split into two or three doses. Start at 25 mg twice daily and increase by 25 mg weekly until you find relief or reach 150 mg daily. Note that many commercial CBD products contain far less CBD per serving than what clinical studies use.

Can I use CBD and THC together for pain?

Yes, and there is evidence suggesting the combination works better than either alone. A 1:1 ratio of THC to CBD is the most studied combination. Start with 2.5 mg of each and titrate upward. CBD may help reduce some of THC’s side effects like anxiety and cognitive impairment while maintaining or enhancing pain relief.

Do CBD topicals actually work for pain?

There is growing evidence that topical CBD can reduce localized pain and inflammation, particularly for conditions like osteoarthritis. The key is concentration — look for products containing at least 8 mg/mL of CBD. Products with very low concentrations (common in gas station and convenience store brands) are unlikely to provide meaningful relief.

How quickly does THC relieve pain?

Inhaled THC provides pain relief within minutes but lasts only 1 to 4 hours. Oral THC (edibles, capsules) takes 30 minutes to 2 hours to take effect but lasts 4 to 8 hours. Sublingual tinctures fall in between, with onset in 15 to 30 minutes. The right delivery method depends on whether you need rapid relief or sustained coverage.

Will CBD show up on a drug test?

Pure CBD should not trigger a positive drug test, as standard tests screen for THC metabolites. However, many CBD products contain trace amounts of THC (up to 0.3% in full-spectrum products), which can accumulate with regular high-dose use and occasionally produce a positive result. CBD isolate products carry the lowest risk, but no CBD product can guarantee a negative drug test.

What types of pain does cannabis not help with?

Evidence is weak or absent for several pain types including acute post-surgical pain (where opioids and NSAIDs remain standard), visceral pain from organ conditions, headaches and migraines (some patient-reported benefit but minimal controlled data), and pain with a significant psychological component where cognitive behavioral therapy and other psychological interventions may be more appropriate.

Are there side effects to using THC for pain?

Yes. Common side effects include dizziness, dry mouth, impaired short-term memory, altered coordination, increased heart rate, and anxiety (particularly at higher doses or in inexperienced users). Most side effects are dose-dependent and diminish with tolerance. Starting at low doses and titrating slowly significantly reduces the likelihood and severity of adverse effects.